These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 8471431)
1. Cisplatin-DNA damage recognition proteins in human tumour extracts. Bissett D; McLaughlin K; Kelland LR; Brown R Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431 [TBL] [Abstract][Full Text] [Related]
2. Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. McLaughlin K; Coren G; Masters J; Brown R Int J Cancer; 1993 Feb; 53(4):662-6. PubMed ID: 8436440 [TBL] [Abstract][Full Text] [Related]
3. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Clugston CK; McLaughlin K; Kenny MK; Brown R Cancer Res; 1992 Nov; 52(22):6375-9. PubMed ID: 1423284 [TBL] [Abstract][Full Text] [Related]
4. Proteins binding to cisplatin-damaged DNA in human cell lines. Billings PC; Engelsberg BN; Hughes EN Cancer Invest; 1994; 12(6):597-604. PubMed ID: 7994594 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro. Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Tanaka T; Masuda H; Naito M; Tamai H Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308 [TBL] [Abstract][Full Text] [Related]
7. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Taverna P; Hansson J; Scanlon KJ; Hill BT Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602 [TBL] [Abstract][Full Text] [Related]
8. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973 [TBL] [Abstract][Full Text] [Related]
9. Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay. Fujiwara Y; Kasahara K; Sugimoto Y; Nishio K; Ohmori T; Saijo N Jpn J Cancer Res; 1990 Dec; 81(12):1210-3. PubMed ID: 2125989 [TBL] [Abstract][Full Text] [Related]
10. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504 [TBL] [Abstract][Full Text] [Related]
11. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899 [TBL] [Abstract][Full Text] [Related]
12. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA. Andrews PA; Jones JA Cancer Commun; 1991 Mar; 3(3):93-102. PubMed ID: 2001331 [TBL] [Abstract][Full Text] [Related]
13. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
14. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864 [TBL] [Abstract][Full Text] [Related]
15. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187 [TBL] [Abstract][Full Text] [Related]
16. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470. Tamura M; Takakuwa K; Tanaka K Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244 [TBL] [Abstract][Full Text] [Related]
17. DNA binding activities of p53 protein following cisplatin damage of ovarian cells. Wetzel CC; Berberich SJ Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726 [TBL] [Abstract][Full Text] [Related]
18. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA. Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934 [TBL] [Abstract][Full Text] [Related]
19. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875 [TBL] [Abstract][Full Text] [Related]
20. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]